November 6, 2019 Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting
Read More
November 6, 2019 Ryvu Therapeutics Reports Third Quarter 2019 Financial Results
Read More
November 5, 2019 Ryvu Therapeutics to Present at BIO-Europe 2019
Read More
October 14, 2019 Ryvu Therapeutics Appoints Chief Medical Officer Setareh Shamsili, M.D., Ph.D., to Executive Management Board
Read More
October 3, 2019 Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
Read More
October 1, 2019 Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland
Read More
September 19, 2019 Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company
Read More
September 6, 2019 Ryvu Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Read More
September 3, 2019 Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split into Two Separately Listed Companies to Proceed
Read More
July 25, 2019 Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer
Read More
Posts navigation
